« Return to News | Clinical Intelligence

Drug improves survival of colorectal cancer patients

Wednesday, January 18, 2012 12:02 PM

Phase II trial results show investigational drug regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, said Mayo Clinic oncologist Axel Grothey, the U.S. trial’s principal investigator.

The trial was randomized, placebo-controlled and conducted simultaneously in the U.S., Europe, Japan, China and Australia. Researchers studied the survival outcomes in 760 patients whose cancer had progressed despite standard chemotherapy regimens.

U.S. results showed patients with metastatic colon cancer who were treated with the drug showed a 29% increase in overall survival when compared to those treated with placebo. The median length of survival increased from 5 months to 6.5 months, a statistically significant jump. Overall, regorafenib reduced patients’ risk of dying from cancer during the trial by 23%.

“For years, patients with metastatic colorectal cancer have faced a devastating impasse when standard chemotherapies have failed to halt the growth of tumors and physicians have run out of effective drugs to offer them,” said Grothey. “This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options.”

Regorafenib is a multi-kinase inhibitor, which has the effect of slowing cell proliferation and blood vessel growth and tempering a variety of biological pathways activated in tumors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.